Zachary Gauge
Head of Research & Strategy Europe ex DACH

Despite a surge in investor interest, UK life sciences remains a very niche real estate sub-sector. For the investment proposition to stack-up, the underlying occupier fundamentals must repay the risks associated with investing in an emerging sector. Despite some challenges, we believe this market offers very strong risk-adjusted returns for early-mover investors who can demonstrate a deep understanding of the underlying occupier market and build long-term relationships with key growth tenants.

Want more insights?

Subscribe to receive the latest private markets perspectives and insights across all sectors directly to your inbox.

Related insights

Contact us

Make an inquiry

Fill in an inquiry form and leave your details – we’ll be back in touch.

Introducing our leadership team

Meet the members of the team responsible for UBS Asset Management’s strategic direction.

Find our offices

We’re closer than you think, find out here.